Search for: "ABBOTT v. WYETH"
Results 61 - 80
of 111
Sorted by Relevance
|
Sort by Date
15 Feb 2011, 5:26 pm
: Novozymes v Danisco (Holman’s Biotech IP Blog) US: Preliminary injunction softened after claims are rejected in reexamination: Celsis In Vitor v CellzDirect (Reexamination Alert) Products Alpharen – EU: General Court: Boards of appeal are judges not doctors! [read post]
11 Dec 2009, 5:00 am
Wyeth, Inc., 85 Cal.Rptr.3d 299 (Cal. [read post]
20 Jan 2011, 12:50 pm
July 3, 2003); Wyeth-Ayerst Laboratories Co. v. [read post]
7 Nov 2014, 5:52 am
Ellis v. [read post]
17 Feb 2012, 4:15 am
In this patent action, Defendants filed a renewed motion to the stay the proceedings pending an inter partes reexamination of the patents-in-suit. [read post]
24 Feb 2010, 2:11 am
Co. v Doll (Filewrapper) US: District Court Massachusetts denies bid for bench trial in RNAi patent suit: Max-Planck-Gesellschaft v Whitehead Institute for Biomedical Research (Patent Docs) US: Court of Appeal for the Ninth Circuit: Federal jurisdiction found in Neuralstem v Reneuron (Patent Docs) US: District Court New Jersey: Disqualification of counsel in patent case requires ‘factual analysis’, not ‘automatic disqualification rule’:… [read post]
24 Feb 2010, 2:11 am
Co. v Doll (Filewrapper) US: District Court Massachusetts denies bid for bench trial in RNAi patent suit: Max-Planck-Gesellschaft v Whitehead Institute for Biomedical Research (Patent Docs) US: Court of Appeal for the Ninth Circuit: Federal jurisdiction found in Neuralstem v Reneuron (Patent Docs) US: District Court New Jersey: Disqualification of counsel in patent case requires ‘factual analysis’, not ‘automatic disqualification rule’:… [read post]
29 May 2014, 5:00 am
Abbott Labs, Inc., 444 F.3d 383, 387-88 (5th Cir. 2006), and Melder v. [read post]
15 Jul 2010, 2:39 pm
Wyeth, Inc., 613 F. [read post]
15 Oct 2008, 3:02 pm
The Supreme Court wil shortly hear these arguments in the context of a drug case and FDA preamble that attempts to grant immunity, when Wyeth v. [read post]
6 Jul 2007, 4:29 am
Wyeth Laboratories, Inc., 533 N.E.2d 748, 755 (Ohio 1988). [read post]
3 Jul 2008, 7:26 pm
Abbott Laboratories, 568 F. [read post]
20 Mar 2009, 6:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Reps Eshoo, Inslee and Barton introduce Pathway for Biosimilars Act (FDA Law Blog) (Patent Docs) (Patent Baristas) (Patent Baristas) (Law360) US: Reps Waxman, Pallone, Deal and Emerson introduce Promoting Innovation and Access to Life-Saving Medicine Act (Intellectual Property Watch) (IPKat) (Patent Docs) EU: Pharma submissions relating to… [read post]
16 Jan 2009, 5:00 am
: BMS v Hetero (GenericsWeb) India: Adding innovation to Ayurveda! [read post]
13 May 2010, 4:58 pm
(Patent Docs) Products Alavert (Loratadine) – US: TTAB vacates WAL-VERT decision per District Court order: Wyeth v Walgreen Co (not precedential) (TTABlog) Axid (Nizatidine), Synthanthic (Oxfendazole) – US: False marking complaint: Baker v. [read post]
21 Feb 2014, 8:53 am
Ramirez v. [read post]
19 Mar 2016, 10:13 am
--Wyeth v. [read post]
27 May 2010, 3:20 am
(Spicy IP) Trilipix (Fenofibrate) – US: Patent infringement complaint following Paragraph IV challenge: Abbott Laboratories et al. v. [read post]
6 May 2016, 12:30 pm
Wyeth Laboratories, 498 F.2d 1264, 1273-74 (5th Cir. 1974) (applying unavoidably unsafe standard without individualized assessment); Holland v. [read post]
17 Oct 2013, 5:00 am
Emody v. [read post]
